May 1 (Reuters) - Eli Lilly and Co LLY.N:
ELI LILLY EXEC SAYS ANNOUNCED TARIFFS CURRENTLY IN EFFECT DO NOT MATERIALLY CHANGE CO'S 2025 FINANCIAL OUTLOOK - CONF CALL
LILLY EXEC SAYS EXPANSION OF TARIFFS IN OTHER GEOGRAPHIES OR INCREASES IN RETALIATORY TARIFFS WOULD HAVE A NEGATIVE EFFECT ON CO, INDUSTRY
LILLY EXEC SAYS RECENTLY INITIATED LIMITED MOUNJARO LAUNCH IN CHINA, EXPECT TO TO GRADUALLY INCREASE LAUNCH IN H2 AS SUPPLY BECOMES AVAILABLE
LILLY EXEC SAYS EXPECT US REGULATORY ACTION FOR MODIFIED DOSING REGIME FOR ALZHEIMER'S DRUG KISUNLA IN THE NEXT FEW MONTHS
LILLY EXEC SAYS PLANS TO START A NEW LATE-STAGE TRIAL FOR ITS DRUG RETATRUTIDE IN PATIENTS WITH OBESITY AND CHRONIC LOW BACK PAIN
LILLY EXEC SAYS CO HAS WITHDRAWN US APPLICATION FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION INDICATION FOR TIRZEPATIDE
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。